Results of a Phase IIb study, presented at the American Association for Cancer Research 101st Annual Meeting 2010, showed a clear clinical benefit from trabedersen, a TGF-beta inhibitor, in patients with high-grade glioma; the Phase III study SAPPHIRE (NCT00761280) is currently enrolling.
"Current therapies for this patient population include surgery, radiation and chemotherapy with temozolomide," said...
Pregnant Woman Undergoes “Kinder, Gentler” Brain Surgery at Saint John’s Health Center Neuroscience Institute by Surgeons Using Brain Port Device
April 19, 2010 10:00 AM Eastern Daylight Time
SANTA MONICA, Calif.--(BUSINESS WIRE)--A unique device developed to make brain surgery easier and less traumatic has been successfully used on a patient who was pregnant and suffering from a potentially life-threatening brain cyst. The device, called a “Brain Port,” was pioneered by...
ScienceDaily (Dec. 3, 2009) — Duke University Medical Center researchers have figured out how stem cells in the malignant brain cancer glioma may be better able to resist radiation therapy. And using a drug to block a particular signaling pathway in these cancer stem cells, they were able to kill many more glioma cells with radiation in a laboratory experiment.
The work builds off earlier research which showed that cancer stem cells resist the effects of radiation much better than other...
Data From Ongoing Phase 2 Trial Consistent with Survival Outcome Reported in Earlier Phase I Trial
October 26, 2009 07:00 AM Eastern Daylight Time
NEW ORLEANS--(BUSINESS WIRE)--Antigenics (NASDAQ: AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO...
